Mads Emil Bjørn

Mads Emil Bjørn

Auto-generated profile, based on publicly available information

Mads Emil Bjørn

Department of Hematology, Zealand University Hospital, Roskilde, Denmark

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2017 in Expert Review of Hematology
Verified
Journal Article
Closed access
MBMads Emil Bjørn
Mads Emil Bjørn
Hans HasselbalchHans Hasselbalch
Hans Hasselbalch
Introduction: The therapeutic landscape of the Philadelphia-negative myeloproliferative neoplasms (MPNs) is markedly changing consequent to the development of JAK-inhibitors and the use of ruxolitinib (RUX) in patients with myelofibrosis (MF) and patients with polycythemia vera (PV) who develop refractoriness or intolerance to hydroxyurea. The use of Interferon-alpha2 (IFN) is rapidly expanding in several countries, based upon favourable safety and efficacy profiles in several single-arm studies during the last 30 years, displaying complete hematological remissions in a large proportion of patients, a reduction in the JAK2V617 F and CALR mutational burden and in a subset of patients with PV with normalisation of the bone marrow after long-term treatment – even being sustained for several years after discontinuation of IFN. To this end the concept of chronic inflammation as the driving force for MPN disease progression is being increasingly recognized. This novel concept has initiated phase II studies in patients with PV and MF of combination therapy with IFN and RUX. Areas covered and Expert commentary: Herein we highlight the background, the rationales and perspectives for this novel combinatorial approach which is foreseen as the most encouraging and promising treatment for patients with MPNs – hopefully with the potential of cure – at least operational cure – in a subset of patients.

15 October 2024 in Blood Advances
Verified
Journal Article
Open access
ASAnders Lindholm Sørensen
Anders Lindholm Sørensen
VSVibe Skov
Vibe Skov
LKLasse Kjær
Lasse Kjær
MBMads Emil Bjørn
Mads Emil Bjørn
CEChristina Schjellerup Eickhardt-Dalbøge
Christina Schjellerup Eickhardt-Dalbøge
Hans HasselbalchHans Hasselbalch
Hans Hasselbalch
We report the 2-year end-of-study results from the phase 2 COMBI II clinical trial investigating the combination treatment of ruxolitinib and low-dose pegylated interferon alfa-2a in patients with newly diagnosed polycythemia vera (PV). The primary outcome was safety and key secondary endpoints were efficacy, based on hematologic parameters, quality-of-life measurements, and JAK2V617F variant allele frequency (VAF). We used the 2013 European LeukemiaNet and International Working Group-Myeloproliferative Neoplasms Research remission criteria. The remission criteria included remissions in symptoms, splenomegaly, peripheral blood counts, and bone marrow. We included 25 patients with PV with a median age of 70 years; 5 of those had prior thromboembolic events and 3 had computed tomography–verified splenomegaly. Two patients stopped both study drugs; 1 of these due to progression to post-PV myelofibrosis, the only one with a grade 3 infection. No events of herpes zoster infections were observed. None of the patients discontinued treatment due to psychiatric symptoms. The peripheral blood cell count remission rate was 92% at 24 months. Using the 2013 European LeukemiaNet and International Working Group-Myeloproliferative Neoplasms Research remission criteria, 14 (56%) achieved remission at 24 months; 3 (12%) achieved complete remission and 11 (44%) achieved partial remission. The following items from the Myeloproliferative Neoplasm Symptom Total Symptom Score were significantly reduced: abdominal discomfort, night sweats, itching, and bone pain. The median JAK2V617F VAF decreased from 47% (95% confidence interval [CI], 35-59) to 7% (95% CI, 3-15), and 60% of patients achieved molecular remission. In conclusion, combination treatment improved cell counts; bone marrow cellularity, and fibrosis; and decreased JAK2V617F VAF; with acceptable toxicity in patients with PV. The trial was registered at www.clinicaltrialsregister.eu as #EudraCT2018-004150-13.

2 September 2026 in Leukemia Research Reports
Verified
Journal Article
Open access
MHMorten Holmström
Morten Holmström
SAShamaila Munir Ahmad
Shamaila Munir Ahmad
UKUffe Klausen
Uffe Klausen
MBMads Emil Bjørn
Mads Emil Bjørn
AGAnne Ortved Gang
Anne Ortved Gang
MAMads Hald Andersen
Mads Hald Andersen